Neuromuscular Blocking Agent (NMBA) Market Insights, Global Outlook and Forecast 2022-2028
Neuromuscular Blocking Agent (NMBA) Market Insights, Global Outlook and Forecast 2022-2028
Neuromuscular Blocking Agent (NMBA) Market by End User (Office Building Construction, Retail Construction, Hospitality Construction, Institutional Construction, Other End Users), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast - is a comprehensive report that provides insights into the market dynamics, including the key drivers, challenges, and opportunities shaping the industry landscape. It also delves into the competitive landscape, highlighting the major players and their strategies.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
The latest research study released by Market IntelliX evaluates market size and forecasts of Neuromuscular Blocking Agent (NMBA) in global, including the following market information:
Global Neuromuscular Blocking Agent (NMBA) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Neuromuscular Blocking Agent (NMBA) Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Neuromuscular Blocking Agent (NMBA) companies in 2021 (%)
The global Neuromuscular Blocking Agent (NMBA) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Depolarizing Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Neuromuscular Blocking Agent (NMBA) include AbbVie, GlaxoSmithKline, Pfizer, Hengrui Pharmaceutical, Abbott Laboratories, Fresenius Kabi, Sandoz, Somerset Therapeutics and Guike Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MI has surveyed the Neuromuscular Blocking Agent (NMBA) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Market Segmentations:
Global Neuromuscular Blocking Agent (NMBA) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Neuromuscular Blocking Agent (NMBA) Market Segment Percentages, by Type, 2021 (%)
Depolarizing
Non-depolarizing
Global Neuromuscular Blocking Agent (NMBA) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Neuromuscular Blocking Agent (NMBA) Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Pharmacy
Others
Global Neuromuscular Blocking Agent (NMBA) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Neuromuscular Blocking Agent (NMBA) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuromuscular Blocking Agent (NMBA) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Neuromuscular Blocking Agent (NMBA) revenues share in global market, 2021 (%)
Key companies Neuromuscular Blocking Agent (NMBA) sales in global market, 2017-2022 (Estimated), (MT)
Key companies Neuromuscular Blocking Agent (NMBA) sales share in global market, 2021 (%)
The report presents profiles of competitors in the market, Some of the prominent key players covered:
AbbVie
GlaxoSmithKline
Pfizer
Hengrui Pharmaceutical
Abbott Laboratories
Fresenius Kabi
Sandoz
Somerset Therapeutics
Guike Pharmaceutical
Shanghai Pharmaceuticals
Themis Medicare
Nanjing King-Friend
Key Takeaways from this Report
Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level – for product types, end use applications and by different industry verticals.
Understand the different dynamics influencing the market – key driving factors, challenges and hidden opportunities.
Get in-depth insights on your competitor performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
Analyze the sales and distribution channels across key geographies to improve top-line revenues.
Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.
Get a quick outlook on the market entropy – M&A’s, deals, partnerships, product launches of all key players for the past 4 years.
Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.
1 Introduction to Research & Analysis Reports
1.1 Neuromuscular Blocking Agent (NMBA) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neuromuscular Blocking Agent (NMBA) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neuromuscular Blocking Agent (NMBA) Overall Market Size
2.1 Global Neuromuscular Blocking Agent (NMBA) Market Size: 2021 VS 2028
2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Neuromuscular Blocking Agent (NMBA) Sales: 2017-2028
3 Company Landscape
3.1 Top Neuromuscular Blocking Agent (NMBA) Players in Global Market
3.2 Top Global Neuromuscular Blocking Agent (NMBA) Companies Ranked by Revenue
3.3 Global Neuromuscular Blocking Agent (NMBA) Revenue by Companies
3.4 Global Neuromuscular Blocking Agent (NMBA) Sales by Companies
3.5 Global Neuromuscular Blocking Agent (NMBA) Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Neuromuscular Blocking Agent (NMBA) Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Neuromuscular Blocking Agent (NMBA) Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neuromuscular Blocking Agent (NMBA) Players in Global Market
3.8.1 List of Global Tier 1 Neuromuscular Blocking Agent (NMBA) Companies
3.8.2 List of Global Tier 2 and Tier 3 Neuromuscular Blocking Agent (NMBA) Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Neuromuscular Blocking Agent (NMBA) Market Size Markets, 2021 & 2028
4.1.2 Depolarizing
4.1.3 Non-depolarizing
4.2 By Type - Global Neuromuscular Blocking Agent (NMBA) Revenue & Forecasts
4.2.1 By Type - Global Neuromuscular Blocking Agent (NMBA) Revenue, 2017-2022
4.2.2 By Type - Global Neuromuscular Blocking Agent (NMBA) Revenue, 2023-2028
4.2.3 By Type - Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share, 2017-2028
4.3 By Type - Global Neuromuscular Blocking Agent (NMBA) Sales & Forecasts
4.3.1 By Type - Global Neuromuscular Blocking Agent (NMBA) Sales, 2017-2022
4.3.2 By Type - Global Neuromuscular Blocking Agent (NMBA) Sales, 2023-2028
4.3.3 By Type - Global Neuromuscular Blocking Agent (NMBA) Sales Market Share, 2017-2028
4.4 By Type - Global Neuromuscular Blocking Agent (NMBA) Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Neuromuscular Blocking Agent (NMBA) Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Pharmacy
5.1.5 Others
5.2 By Application - Global Neuromuscular Blocking Agent (NMBA) Revenue & Forecasts
5.2.1 By Application - Global Neuromuscular Blocking Agent (NMBA) Revenue, 2017-2022
5.2.2 By Application - Global Neuromuscular Blocking Agent (NMBA) Revenue, 2023-2028
5.2.3 By Application - Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share, 2017-2028
5.3 By Application - Global Neuromuscular Blocking Agent (NMBA) Sales & Forecasts
5.3.1 By Application - Global Neuromuscular Blocking Agent (NMBA) Sales, 2017-2022
5.3.2 By Application - Global Neuromuscular Blocking Agent (NMBA) Sales, 2023-2028
5.3.3 By Application - Global Neuromuscular Blocking Agent (NMBA) Sales Market Share, 2017-2028
5.4 By Application - Global Neuromuscular Blocking Agent (NMBA) Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Neuromuscular Blocking Agent (NMBA) Market Size, 2021 & 2028
6.2 By Region - Global Neuromuscular Blocking Agent (NMBA) Revenue & Forecasts
6.2.1 By Region - Global Neuromuscular Blocking Agent (NMBA) Revenue, 2017-2022
6.2.2 By Region - Global Neuromuscular Blocking Agent (NMBA) Revenue, 2023-2028
6.2.3 By Region - Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share, 2017-2028
6.3 By Region - Global Neuromuscular Blocking Agent (NMBA) Sales & Forecasts
6.3.1 By Region - Global Neuromuscular Blocking Agent (NMBA) Sales, 2017-2022
6.3.2 By Region - Global Neuromuscular Blocking Agent (NMBA) Sales, 2023-2028
6.3.3 By Region - Global Neuromuscular Blocking Agent (NMBA) Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Neuromuscular Blocking Agent (NMBA) Revenue, 2017-2028
6.4.2 By Country - North America Neuromuscular Blocking Agent (NMBA) Sales, 2017-2028
6.4.3 US Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.4.4 Canada Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.4.5 Mexico Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Neuromuscular Blocking Agent (NMBA) Revenue, 2017-2028
6.5.2 By Country - Europe Neuromuscular Blocking Agent (NMBA) Sales, 2017-2028
6.5.3 Germany Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.5.4 France Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.5.5 U.K. Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.5.6 Italy Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.5.7 Russia Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.5.8 Nordic Countries Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.5.9 Benelux Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Neuromuscular Blocking Agent (NMBA) Revenue, 2017-2028
6.6.2 By Region - Asia Neuromuscular Blocking Agent (NMBA) Sales, 2017-2028
6.6.3 China Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.6.4 Japan Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.6.5 South Korea Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.6.6 Southeast Asia Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.6.7 India Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Neuromuscular Blocking Agent (NMBA) Revenue, 2017-2028
6.7.2 By Country - South America Neuromuscular Blocking Agent (NMBA) Sales, 2017-2028
6.7.3 Brazil Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.7.4 Argentina Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales, 2017-2028
6.8.3 Turkey Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.8.4 Israel Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.8.5 Saudi Arabia Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
6.8.6 UAE Neuromuscular Blocking Agent (NMBA) Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 AbbVie
7.1.1 AbbVie Corporate Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.1.5 AbbVie Key News
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Corporate Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.2.5 GlaxoSmithKline Key News
7.3 Pfizer
7.3.1 Pfizer Corporate Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.3.5 Pfizer Key News
7.4 Hengrui Pharmaceutical
7.4.1 Hengrui Pharmaceutical Corporate Summary
7.4.2 Hengrui Pharmaceutical Business Overview
7.4.3 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.4.5 Hengrui Pharmaceutical Key News
7.5 Abbott Laboratories
7.5.1 Abbott Laboratories Corporate Summary
7.5.2 Abbott Laboratories Business Overview
7.5.3 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.5.5 Abbott Laboratories Key News
7.6 Fresenius Kabi
7.6.1 Fresenius Kabi Corporate Summary
7.6.2 Fresenius Kabi Business Overview
7.6.3 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.6.5 Fresenius Kabi Key News
7.7 Sandoz
7.7.1 Sandoz Corporate Summary
7.7.2 Sandoz Business Overview
7.7.3 Sandoz Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.7.4 Sandoz Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.7.5 Sandoz Key News
7.8 Somerset Therapeutics
7.8.1 Somerset Therapeutics Corporate Summary
7.8.2 Somerset Therapeutics Business Overview
7.8.3 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.8.5 Somerset Therapeutics Key News
7.9 Guike Pharmaceutical
7.9.1 Guike Pharmaceutical Corporate Summary
7.9.2 Guike Pharmaceutical Business Overview
7.9.3 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.9.5 Guike Pharmaceutical Key News
7.10 Shanghai Pharmaceuticals
7.10.1 Shanghai Pharmaceuticals Corporate Summary
7.10.2 Shanghai Pharmaceuticals Business Overview
7.10.3 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.10.5 Shanghai Pharmaceuticals Key News
7.11 Themis Medicare
7.11.1 Themis Medicare Corporate Summary
7.11.2 Themis Medicare Neuromuscular Blocking Agent (NMBA) Business Overview
7.11.3 Themis Medicare Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.11.4 Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.11.5 Themis Medicare Key News
7.12 Nanjing King-Friend
7.12.1 Nanjing King-Friend Corporate Summary
7.12.2 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Business Overview
7.12.3 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Major Product Offerings
7.12.4 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales and Revenue in Global (2017-2022)
7.12.5 Nanjing King-Friend Key News
8 Global Neuromuscular Blocking Agent (NMBA) Production Capacity, Analysis
8.1 Global Neuromuscular Blocking Agent (NMBA) Production Capacity, 2017-2028
8.2 Neuromuscular Blocking Agent (NMBA) Production Capacity of Key Manufacturers in Global Market
8.3 Global Neuromuscular Blocking Agent (NMBA) Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Neuromuscular Blocking Agent (NMBA) Supply Chain Analysis
10.1 Neuromuscular Blocking Agent (NMBA) Industry Value Chain
10.2 Neuromuscular Blocking Agent (NMBA) Upstream Market
10.3 Neuromuscular Blocking Agent (NMBA) Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Neuromuscular Blocking Agent (NMBA) Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
Research Methodology:
Neuromuscular Blocking Agent (NMBA) Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|